文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于计算机预测的利什曼原虫候选肽疫苗的免疫原性和免疫调节作用。

Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.

机构信息

Institute of Endemic Diseases, University of Khartoum, Khartoum, Sudan.

出版信息

Hum Vaccin Immunother. 2012 Dec 1;8(12):1769-74. doi: 10.4161/hv.21881. Epub 2012 Aug 24.


DOI:10.4161/hv.21881
PMID:22922767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3656064/
Abstract

Visceral leishmaniasis (VL) is a serious parasitic disease for which control measures are limited and drug resistance is increasing. First and second generation vaccine candidates have not been successful. The goal of the present study was to select possibly immunogenic L. donovani donovani GP63 peptides using immunoinformatics tools and to test their immunogenicity in vitro. The amino acid sequence of L. donovani donovani GP63 [GenBank accession: ACT31401] was screened using the EpiMatrix algorithm for putative T cell epitopes that would bind to the most common HLA class II alleles (DRB11101 and DRB10804) among at-risk populations. Four T cell epitopes were selected from nine potential candidates. Stimulation of whole blood from healthy volunteers using the peptides separately produced mean IFN-γ and IL-4 levels that were not significantly different from negative controls, while the pooled peptides produced a moderate IFN-γ increase in some volunteers. However, mean IL-10 levels were significantly reduced for all individuals compared with controls. The immunogenicity of these epitopes may be harnessed most effectively in a vaccine delivered in combination with immune-modulating adjuvants.

摘要

内脏利什曼病(VL)是一种严重的寄生虫病,其控制措施有限,且耐药性正在增加。第一代和第二代疫苗候选物都没有成功。本研究的目的是使用免疫信息学工具选择可能具有免疫原性的利什曼原虫 GP63 肽,并在体外测试其免疫原性。使用 EpiMatrix 算法筛选利什曼原虫 GP63 [GenBank 登录号:ACT31401]的氨基酸序列,以寻找可能与高危人群中最常见的 HLA Ⅱ类等位基因(DRB11101 和 DRB10804)结合的 T 细胞表位。从九个潜在候选物中选择了四个 T 细胞表位。单独使用这些肽刺激健康志愿者的全血产生的 IFN-γ 和 IL-4 水平与阴性对照没有显著差异,而混合肽在一些志愿者中产生了适度的 IFN-γ 增加。然而,与对照组相比,所有个体的平均 IL-10 水平均显著降低。与免疫调节佐剂联合使用疫苗可以最有效地利用这些表位的免疫原性。

相似文献

[1]
Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.

Hum Vaccin Immunother. 2012-8-24

[2]
Prediction and analysis of promiscuous T cell-epitopes derived from the vaccine candidate antigens of Leishmania donovani binding to MHC class-II alleles using in silico approach.

Infect Genet Evol. 2017-9

[3]
Immuno-informatics based approaches to identify CD8+ T cell epitopes within the Leishmania donovani 3-ectonucleotidase in cured visceral leishmaniasis subjects.

Microbes Infect. 2017-6

[4]
An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.

Parasit Vectors. 2020-4-15

[5]
Evaluating the immunomodulatory responses of LdODC-derived MHC Class-II restricted peptides against VL.

Parasite Immunol. 2020-2-6

[6]
gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.

Infect Immun. 2008-3

[7]
115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.

Immunobiology. 2012-2-16

[8]
Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.

Parasitology. 2018-4

[9]
Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.

PLoS Negl Trop Dis. 2011-12-20

[10]
Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response.

Cytokine. 2018-7-9

引用本文的文献

[1]
Vaccine efficacy induced by virus-like particles containing Leishmania donovani surface glycoprotein GP63.

PLoS Negl Trop Dis. 2024-6

[2]
A New Strategy for Mapping Epitopes of LACK and PEPCK Proteins of Specific for Major Histocompatibility Complex Class I.

Int J Mol Sci. 2023-3-22

[3]
Immunoinformatics Approach to Design a Multi-Epitope Vaccine against Cutaneous Leishmaniasis.

Vaccines (Basel). 2023-2-2

[4]
Polylactide Nanoparticles as a Biodegradable Vaccine Adjuvant: A Study on Safety, Protective Immunity and Efficacy against Human Leishmaniasis Caused by Leishmania Major.

Molecules. 2022-12-8

[5]
An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.

Parasit Vectors. 2020-4-15

[6]
Design of multi-epitope peptides containing HLA class-I and class-II-restricted epitopes derived from immunogenic Leishmania proteins, and evaluation of CD4+ and CD8+ T cell responses induced in cured cutaneous leishmaniasis subjects.

PLoS Negl Trop Dis. 2020-3-16

[7]
Peptide Vaccines for Leishmaniasis.

Front Immunol. 2018-5-11

[8]
Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.

Front Immunol. 2017-12-21

[9]
Identification of Potential MHC Class-II-Restricted Epitopes Derived from Antigens by Reverse Vaccinology and Evaluation of Their CD4+ T-Cell Responsiveness against Visceral Leishmaniasis.

Front Immunol. 2017-12-14

[10]
Designing a DNA Vaccine-based Polytope (Preliminary Report).

Iran J Parasitol. 2017

本文引用的文献

[1]
IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis.

J Infect Dis. 2011-10-1

[2]
Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for Leishmania donovani, a proof of concept study.

PLoS Negl Trop Dis. 2011-4-19

[3]
Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study.

PLoS Negl Trop Dis. 2010-10-26

[4]
Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.

PLoS Negl Trop Dis. 2010-10-26

[5]
Quantification of parasite load in clinical samples of leishmaniasis patients: IL-10 level correlates with parasite load in visceral leishmaniasis.

PLoS One. 2010-4-9

[6]
A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.

Vaccine. 2009-2-11

[7]
Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.

Trans R Soc Trop Med Hyg. 2008-1

[8]
Cutaneous leishmaniasis.

Lancet Infect Dis. 2007-9

[9]
More than one reason to rethink the use of peptides in vaccine design.

Nat Rev Drug Discov. 2007-5

[10]
New tools, new approaches and new ideas for vaccine development.

Expert Rev Vaccines. 2007-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索